Pharmaceutical compound
Clinical data | |
---|---|
ATC code |
|
Legal status | |
Legal status |
|
Identifiers | |
IUPAC name
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
KEGG | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C20H21F3N2O2 |
Molar mass | 378.395 g·mol |
3D model (JSmol) | |
SMILES
| |
InChI
|
Tilapertin (INN), also known as AMG-747, is a investigational drug which was being evaluated as an antipsychotic.
Mechanism of action
Tilapertin appears to act via the blocking of the type 1 glycine transporter, making it a glycine re-uptake inhibitor.
History
Two studies have been made in order to determine the safety of tilapertin and its potential as an add-on to anti-psychotic therapy in people with schizophrenia. These studies were later halted due to a case of Stevens–Johnson syndrome in one of the participants.
See also
References
- "Tilapertin". PubChem. U.S. National Library of Medicine. Retrieved 2024-08-16.
- World Health Organization (2013). "International Nonproprietary Names for Pharmaceutical Substances (INN): Proposed INN: List 110" (PDF). WHO Drug Information. 27 (4). World Health Organization.
- ^ Dunayevich E, Buchanan RW, Chen CY, Yang J, Nilsen J, Dietrich JM, et al. (April 2017). "Efficacy and safety of the glycine transporter type-1 inhibitor AMG 747 for the treatment of negative symptoms associated with schizophrenia". Schizophrenia Research. 182: 90–97. doi:10.1016/j.schres.2016.10.027. PMID 27789188.
This drug article relating to the nervous system is a stub. You can help Misplaced Pages by expanding it. |